Business Context and Reporting Period
Protagonist Therapeutics, Inc. (PTGX) filed this Form 8-K on October 30, 2019, to report the entry into a material definitive agreement. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Debt Structure
The filing details a new Term Loan Credit Agreement with a total facility size of $50.0 million. The financial structure includes:
- Initial Funding: $10.0 million principal amount funded on the closing date.
- Optional Tranches: Up to $20.0 million available until December 31, 2020, and an additional $20.0 million available until September 30, 2021, subject to conditions.
- Interest Rate: WSJ Prime Rate plus 2.91%, with a floor of 4.94%.
- Repayment Terms: Interest-only payments for 24 months commencing November 1, 2019, followed by 24 months of amortization. Full maturity is October 1, 2023.
- Fees: 0.25% origination fee per tranche. Prepayment premiums range from 3.0% to 1.0% depending on the timing, plus an additional 2.85% of the advanced amount due upon prepayment or repayment.
- Collateral: Secured by a perfected security interest in all Company assets, excluding intellectual property and certain customary exclusions.
- Liquidity Covenant: The Company must maintain cash and cash equivalents of at least 35% of the outstanding Term Loans at all times.
The filing text does not provide current revenue, profit, cash flow, or margin data, as this is a current report regarding a specific financing event rather than a periodic financial statement.
Material Changes
The primary material change is the creation of a new direct financial obligation. The Company has secured a credit facility to fund general corporate purposes, altering its capital structure and introducing new debt service obligations and covenants.
Outlook, Risks, and Contingencies
Management Commentary: Proceeds are intended for general corporate purposes.
Risks and Covenants: The agreement includes customary affirmative and negative covenants restricting indebtedness, liens, investments, mergers, and dividends. Events of default include payment failures, insolvency, material misrepresentations, and specific regulatory actions by the FDA or DEA that could result in a Material Adverse Change.
Contingencies: The availability of the additional $40.0 million in optional tranches is contingent upon the satisfaction of certain conditions not detailed in this summary.
Investor Verification Checklist
- Verify the Company's current cash balance to ensure compliance with the 35% liquidity covenant relative to the $10.0 million initial draw.
- Review the specific conditions required to access the optional $20.0 million tranches.
- Assess the impact of the 2.85% additional prepayment fee on future capital flexibility.
- Monitor FDA or DEA regulatory developments that could trigger a Material Adverse Change event of default.
- Confirm the total outstanding debt load including this new facility against the Company's projected cash burn rate.